Praxis Precision Medicines (PRAX) Return on Capital Employed (2020 - 2026)

Praxis Precision Medicines' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 31.1% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 2168.0% year-over-year to 31.1% in Q1 2026; TTM through Mar 2026 was 31.1%, a 2168.0% increase from a year earlier, with the FY2025 full-year figure at 50.13%, up 3059.0% from the prior year.
• Return on Capital Employed grew to 31.1% in Q1 2026 per PRAX's latest filing, from 53.71% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 31.1% in Q1 2026 and bottomed at 239.76% in Q1 2023.
• The 5-year median for Return on Capital Employed is 86.56% (2024), against an average of 108.61%.
• Across the five-year window, Return on Capital Employed plunged 17258 bps in 2022 and jumped 15320 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 234.52% in 2022, then surged by 34 bps to 154.89% in 2023, then surged by 69 bps to 48.57% in 2024, then dropped by 11 bps to 53.71% in 2025, then surged by 42 bps to 31.1% in 2026.
• Per Business Quant, the three latest PRAX Return on Capital Employed figures stand at 31.1% (Q1 2026), 53.71% (Q4 2025), and 78.85% (Q3 2025).